A detailed history of Voya Investment Management LLC transactions in Arcutis Biotherapeutics, Inc. stock. As of the latest transaction made, Voya Investment Management LLC holds 34,608 shares of ARQT stock, worth $320,470. This represents 0.0% of its overall portfolio holdings.

Number of Shares
34,608
Previous 35,414 2.28%
Holding current value
$320,470
Previous $329,000 2.43%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$8.32 - $11.0 $6,705 - $8,866
-806 Reduced 2.28%
34,608 $321,000
Q2 2024

Aug 14, 2024

BUY
$7.24 - $12.53 $67,027 - $116,002
9,258 Added 35.4%
35,414 $329,000
Q1 2024

May 15, 2024

SELL
$3.25 - $11.77 $217,932 - $789,249
-67,056 Reduced 71.94%
26,156 $259,000
Q4 2023

Feb 14, 2024

BUY
$1.84 - $4.82 $101,071 - $264,762
54,930 Added 143.49%
93,212 $301,000
Q3 2023

Nov 14, 2023

BUY
$5.31 - $10.98 $3,754 - $7,762
707 Added 1.88%
38,282 $203,000
Q2 2023

Aug 14, 2023

BUY
$7.51 - $15.0 $37,129 - $74,160
4,944 Added 15.15%
37,575 $358,000
Q1 2023

May 15, 2023

SELL
$10.23 - $17.14 $28,030 - $46,963
-2,740 Reduced 7.75%
32,631 $358,000
Q3 2022

Nov 14, 2022

BUY
$17.85 - $26.95 $397,091 - $599,529
22,246 Added 169.49%
35,371 $676,000
Q2 2022

Aug 15, 2022

BUY
$16.33 - $22.2 $38,947 - $52,947
2,385 Added 22.21%
13,125 $280,000
Q4 2021

Feb 14, 2022

SELL
$14.98 - $25.5 $584 - $994
-39 Reduced 0.36%
10,740 $223,000
Q2 2021

Aug 16, 2021

BUY
$24.42 - $34.75 $32,796 - $46,669
1,343 Added 14.23%
10,779 $294,000
Q1 2021

May 17, 2021

BUY
$24.47 - $36.98 $24,543 - $37,090
1,003 Added 11.89%
9,436 $273,000
Q4 2020

Feb 16, 2021

BUY
$17.82 - $31.73 $150,276 - $267,579
8,433 New
8,433 $237,000

Others Institutions Holding ARQT

About Arcutis Biotherapeutics, Inc.


  • Ticker ARQT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 60,187,500
  • Market Cap $557M
  • Description
  • Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing A...
More about ARQT
Track This Portfolio

Track Voya Investment Management LLC Portfolio

Follow Voya Investment Management LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Voya Investment Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Voya Investment Management LLC with notifications on news.